Simvastatin reprograms lipid metabolism in B16.F10 melanoma cells to favor an early resistant phenotype
Giorgiana-Gabriela Negrea, Loredana Balacescu, Ilie Ovidiu Pavel, Alina Sesarman, Manuela Banciu · 2026
Read Simvastatin reprograms lipid metabolism in B16.F10 melanoma cells to favor an early resistant phenotype by Giorgiana-Gabriela Negrea, Loredana Balacescu, Ilie Ovidiu Pavel, Alina Sesarman, Manuela Banciu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13396812.txt.
Description
Giorgiana-Gabriela Negrea and four co-authors report a 2026 study of how simvastatin reshapes fat metabolism in melanoma cells. Prior work by the group showed the drug slowed growth of a mouse melanoma line. That held in the lab and in animals. The drug cut a protein that helps cancer cells adapt to low oxygen.
Cells can also show that protein when oxygen is normal. There it links to more aggressive growth. The team read gene and protein changes under normal oxygen, next to two control factors. Their data say the drug steers glucose use to refill cell stores, which may favor an early resistant state.
Catalog record
| CREATOR | Giorgiana-Gabriela Negrea, Loredana Balacescu, Ilie Ovidiu Pavel, Alina Sesarman, Manuela Banciu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 90 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |